This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Mink Therapeutics, Inc.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Marc Van Dijk: Innovator in Engineered Host Cells
Introduction
Marc Van Dijk is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of biotechnology, particularly in the development of engineered host cells. His work focuses on enhancing the expression of functional T cell receptors, which are crucial for immune response.
Latest Patents
Marc Van Dijk holds a patent for "Engineered host cells and methods of use thereof." This patent describes engineered host cells that are suitable for the expression of functional T cell receptors (TCRs). The methods outlined in the patent enable the identification of TCRs that specifically bind to desired peptide-major histocompatibility complex (MHC) complexes. He has 1 patent to his name.
Career Highlights
Marc is currently associated with Mink Therapeutics, Inc., where he continues to innovate in the field of immunotherapy. His work has the potential to advance treatments for various diseases by improving the efficacy of T cell therapies.
Collaborations
Throughout his career, Marc has collaborated with notable professionals in the field, including Volker Seibert and Robert Benjamin Stein. These collaborations have further enriched his research and development efforts.
Conclusion
Marc Van Dijk is a key figure in the advancement of engineered host cells, with a focus on T cell receptor expression. His innovative work at Mink Therapeutics, Inc. and his patent contributions highlight his commitment to improving therapeutic strategies in immunology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile